Assembly Biosciences, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Assembly Biosciences, Inc. (Nasdaq: ASMB) is a clinical-stage biotechnology company focused on developing innovative antiviral therapeutics targeting viral diseases with unmet medical needs, including hepatitis B virus (HBV), norovirus, and other viral infections. The company discovers, develops, and advances small-molecule antiviral agents through preclinical and clinical stages; its pipeline features emvododstat, a next-generation oral, selective, small-molecule inhibitor of diaminopimelate aminotransferase (DAPTAse) in Phase 2 development for HBV; ABI-4334, an optimized core inhibitor candidate advancing toward Phase 1; and earlier-stage programs against norovirus and dengue. Assembly Biosciences operates primarily in the United States, with headquarters in South San Francisco, California, founded in 2010 as a leader in microbiome therapeutics before pivoting to virology in recent years. Recent strategic shifts include the discontinuation of its microbiome gastrointestinal program in 2022 to concentrate resources on virology; in 2024, the company reported positive interim data from the Phase 2a SYNERGY-HBV trial for emvododstat, supporting dose selection and combination potential with nucleos(t)ide analogues; and in October 2024, Assembly Biosciences announced the selection of ABI-4334 as a development candidate following extensive optimization efforts. No major acquisitions, funding rounds, or partnerships were reported in the last 1-2 years, though the company continues to advance its HBV portfolio toward potential registrational studies. Assembly Biosciences targets patients and healthcare providers in the antiviral therapeutics market, with operations centered in the U.S. biopharma hub.
Assembly Biosciences Teases Gilead HSV-2 Decision, Liver Disease Data Ahead
Assembly Biosciences, Inc. (ASMB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Assembly Biosciences Eyes Gilead HSV Plan as ABI-6250 Liver Pipeline Expands
Assembly Biosciences Announces Upcoming Investor Conference Presentations
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference
Assembly Biosciences, Inc. (ASMB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference
Assembly Biosciences (ASMB) Reports Q1 Loss, Misses Revenue Estimates
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026
Brokerages Set Assembly Biosciences, Inc. (NASDAQ:ASMB) PT at $41.75
Assembly Biosciences: 'Buy' On HPI Program Opt-In And HDV Candidate Development
Assembly Biosciences (ASMB) Q4 Earnings and Revenues Top Estimates
Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above 200 Day Moving Average – Here’s Why